Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study - Université de Tours Accéder directement au contenu
Article Dans Une Revue Acta Oncologica Année : 2022

Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study

1 Département d'Hématologie [CHU Nantes]
2 Hôpital Claude Huriez [Lille]
3 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
4 Université de Lille
5 Institut Curie [Paris]
6 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
7 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
8 CIMI - Centre d'Immunologie et des Maladies Infectieuses
9 IPC - Institut Paoli-Calmettes
10 CRCM - Centre de Recherche en Cancérologie de Marseille
11 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
12 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
13 Hôpital Necker - Enfants Malades [AP-HP]
14 Institut Jules Bordet [Bruxelles]
15 ULB - Université libre de Bruxelles
16 Cliniques universitaires St Luc [Bruxelles]
17 CHU de Poitiers - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
18 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
19 LNOx - ERL 7001 LNOx (Leukemic Niche & redOx metabolism / Niche leucémique et métabolisme redOx)
20 CHU Nice - Centre Hospitalier Universitaire de Nice
21 UniCA - Université Côte d'Azur
22 CHU Angers - Centre Hospitalier Universitaire d'Angers
23 CHU-Liège - Centre Hospitalier Universitaire de Liège
24 CHU Saint-Antoine [AP-HP]
25 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
26 UM - Université de Montpellier
27 CHU Estaing [Clermont-Ferrand]
28 CHU Nantes - Centre Hospitalier Universitaire de Nantes
29 FHU GOAL - Fédérations hospitalo-universitaires Grand Ouest Acute Leukemia [Angers]
30 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
31 Laboratoire d'Hematologie [CHU Nantes]
Benoit Tessoullin
  • Fonction : Auteur
Carmen Botella-Garcia
  • Fonction : Auteur

Résumé

Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting. Material and Methods: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined. Results: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5-157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33-70), 47% (95%CI: 33-68) and 38.5% (95%CI: 25-60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18-50) and 18% (95%CI: 7-34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32-28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52-32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured. Conclusion: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions.

Dates et versions

hal-04084965 , version 1 (28-04-2023)

Identifiants

Citer

Baptiste Le Calvez, Benoit Tessoullin, Loic Renaud, Carmen Botella-Garcia, Micha Srour, et al.. Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. Acta Oncologica, 2022, 61 (11), pp.1332-1338. ⟨10.1080/0284186X.2022.2130709⟩. ⟨hal-04084965⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More